key: cord-0961867-vt9mhkmg
authors: Trinité, Benjamin; Pradenas, Edwards; Marfil, Silvia; Rovirosa, Carla; Urrea, Víctor; Tarrés-Freixas, Ferran; Ortiz, Raquel; Vergara-Alert, Júlia; Segalés, Joaquim; Guallar, Victor; Lepore, Rosalba; Izquierdo-Useros, Nuria; Trujillo, Glòria; Trapé, Jaume; González-Fernández, Carolina; Flor, Antonia; Pérez-Vidal, Rafel; Chamorro, Anna; Paredes, Roger; Blanco, Ignacio; Grau, Eulalia; Massanella, Marta; Carrillo, Jorge; Clotet, Bonaventura; Blanco, Julià
title: Previous SARS-CoV-2 infection increases B.1.1.7 cross-neutralization by vaccinated individuals
date: 2021-03-05
journal: bioRxiv
DOI: 10.1101/2021.03.05.433800
sha: a2b15daee8b6f3708f68be2b49b2b080098855a9
doc_id: 961867
cord_uid: vt9mhkmg

To assess the potential impact of predominant circulating SARS-CoV-2 variants on neutralizing activity of infected and/or vaccinated individuals, we analyzed neutralization of pseudoviruses expressing the spike of the original Wuhan strain, the D614G and B.1.1.7 variants. Our data show that parameters of natural infection (time from infection and infecting variant) determined cross-neutralization. Importantly, upon vaccination, previously infected individuals developed equivalent B.1.1.7 and Wuhan neutralizing responses. In contrast, uninfected vaccinees showed reduced neutralization against B.1.1.7. Funding This study was funded by Grifols, the Departament de Salut of the Generalitat de Catalunya, the Spanish Health Institute Carlos III, CERCA Programme/Generalitat de Catalunya, and the crowdfunding initiatives #joemcorono, BonPreu/Esclat and Correos.

The variant B.1.1.7 or 501Y.V1 has rapidly spread across Europe (1) . Besides the D614G mutation, this variant contains 6 mutations and 3 deleted amino acids in the Spike protein.

Major changes are the mutation N501Y in the Receptor Binding Domain (RBD); the deletion 69-70 which may increase transmissibility (2) and produces false negative in certain RT-PCR based diagnostic assays; and the mutation P681H, next to the furin cleavage site, that could impact antigenicity and enhance viral infectivity. Although there is no convincing evidence that B.1.1.7 causes more severe disease, several reports indicate that B.1.1.7 has a higher secondary attack rate making this viral variant 30-50% more transmissible (3) . Importantly, this variant remains susceptible to some monoclonal and plasma antibodies from convalescent or vaccinated individuals (4-6).

To comparatively evaluate infectivity and neutralization sensitivity, we constructed HIV-1-based pseudoviruses expressing different variants of the S protein of SARS-CoV-2 as reported (7): the original sequence (Wuhan); the single point mutant D614G which developed during the first European outbreak and became ubiquitous at subsequent outbreaks; and the B.1.1.7 variant, that has recently become predominant in Europe ( Figure 1A ). The neutralization of plasma samples was assessed using pseudoviruses as previously described (8) Figure 1C ). However, this value was significantly different from the value obtained in vaccinees (M-W test, Figure 2 ). To understand these differences, we analyzed infected and vaccinated subgroups. To assess the impact of sequence evolution on the immune responses, infected individuals were grouped according to infection date. Individuals infected during the first wave (March 2020) were exposed in majority to the D614-containing variants (60% prevalence at that time in Spain), while individuals infected during the second wave (August 2020) were largely exposed to the G614-containing 20E(EU1) lineage, which accounted for infection, a wider analysis will be necessary to dissect the contribution of each factor. In addition, our data do not allow us to draw any conclusion on the long-term evolution of immune responses elicited by vaccines, in terms of quality of antibodies or durability.

In summary, we show that increased infectivity, in vitro, of the B.1.1.7 variant minimally impacts sensitivity to neutralizing immune responses from infected and/or vaccinated individuals, as previously reported (4,11). Importantly, our data suggest that previous infection contributes to a better neutralization of B.1.1.7 variant in vaccinees, being the uninfected vaccinees the individuals showing a more evident, although small in magnitude, loss of neutralization (12, 13) . Both wider diversity and evolution of the antibody repertoire could contribute to this effect (14) , which is also observed in infected non-vaccinated individuals ( Figure 3A ). In line with other reports (15) 

Early transmissibility assessment of the N501Y mutant strains of SARS-CoV-2 in the United Kingdom

Recurrent emergence and transmission of a SARS-CoV-2 Spike deletion ∆H69/V70

Estimated transmissibility and impact of SARS-CoV-2 lineage B.1.1.7 in England

Impact of B.1.1.7 variant mutations on antibody recognition of linear SARS-CoV-2 epitopes

Neutralization of SARS-CoV-2 lineage B.1.1.7 pseudovirus by BNT162b2 vaccine-elicited human sera

Increased Resistance of SARS-CoV-2 Variants B.1.351 and B.1.1.7 to Antibody Neutralization

SARS-CoV-2 infection elicits a rapid neutralizing antibody response that correlates with disease severity. Sci Rep

Stable neutralizing antibody levels six months after mild and severe COVID-19 episode

Emerging SARS-CoV-2 variants reduce neutralization sensitivity to convalescent sera and monoclonal antibodies

Evolution of antibody immunity to SARS-CoV-2

Impact of SARS-CoV-2 B.1.1.7 Spike variant on neutralisation potency of sera from individuals vaccinated with Pfizer vaccine BNT162b2. medRxiv

mRNA vaccine-elicited antibodies to SARS-CoV-2 and circulating variants 2 3. bioRxiv

Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK. Lancet

Preexisting and de novo humoral immunity to SARS-CoV-2 in humans

Reduced antibody crossreactivity following infection with B . 1 . 1 . 7 than with parental SARS -CoV -2 strains